New PET imaging agents in the management of solid cancers

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 748-755

  Garcia, Camilo ^a   Gebhart, Geraldine ^a   Flamen, Patrick ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

PET

Indexed keywords

EID: 85027921939     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835766f7     Document Type: Review

References (37)

1. van den Abbeele AD. The lessons of GIST, PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 (Suppl 2):8-13.
2. Nanni C, Fantini L, Nicolini S, et al. Non FDG PET. Clin Radiol 2010; 65:536-548.
3. Gilbert FJ, Fleming IN, Marsden PK. Beyond 18F-fluorodeoxyglucose: making the next generation of PET radiotracers available for oncology research in the UK. Nucl Med Commun 2011; 32:1-3.
4. Nuñez Miller R, Pozo MA. Non FDG-PET in oncology. Clin Transl Oncol 2011; 13:780-786; DOI 10.1007/s12094-011-0733-7.
5. Muijs CT, Beukema JC, Widder J, et al. 18F-FLT-PET for detection of rectal cancer. Radiother Oncol 2011; 98:357-359.
6. Zander T, Scheffler M, Nogova L, et al. Early prediction of nonprogression in advanced nonsmall-cell lung cancer treated with erlotinib by using [(18)F] fluorodeoxyglucose and [(18)F] fluorothymidine positron emission tomography. J Clin Oncol 2011; 29:1701-1708.
7. Mileshkin L, Hicks RJ, Hughes BG, et al. Changes in 18F- fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with nonsmall cell lung cancer treated with erlotinib. Clin Cancer Res 2011; 17:3304-3315.
8. Pfannenberg C, Aschoff P, Dittmann H, et al. PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 2010; 51:845-853.
9. Yang W, Zhang Y, Fu Z, et al. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in nonsmall-cell lung cancer. Eur J Nucl Med Mol Imaging 2010; 37:1291-1299.
10. Ambrosini V, Tomassetti P, Franchi R, et al. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010; 54:16-23.
11. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2010; 37:2004-2010.
12. Oberg K, Akerström G, Rindi G, et al., ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5):v223-v227.
13. Campana D, Ambrosini V, Pezzilli R, et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51:353-359.
14. Rufini V, Treglia G, Castaldi P, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 2011; 32:575-582.
15. Charrier N, Deveze A, Fakhry N, et al. Comparison of [111In] pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf) 2011; 74:21-29.
16. Fottner C, Helisch A, Anlauf M, et al. 6-18F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010; 95:2800-2810.
17. Ambrosini V, Tomassetti P, Castellucci P, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastroentero-gastroentero- pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35:1431-1438.
18. Putzer D, Gabriel M, Kendler D, et al. Comparison of (68)Ga-DOTA-Tyr(3)- octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010; 54:68-75.
19. Haug A, Auernhammer CJ, Wängler B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36:765-770.
20. Tessonnier L, Sebag F, Ghander C, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 2010; 95:303-307.
21. Marzola MC, Pelizzo MR, Ferdeghini M, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010; 36:414-421.
22. Withofs N,Grayet B, Tancredi T, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32:168-176.
23. Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med 2010; 51: 1813-1820.
24. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase
25. Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254:925-933.
26. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009; 11:446-454.
27. McCarthy M, Siew T, Campbell A, et al. 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011; 38:14-22.
28. Talbot JN, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51:1699-1706.
29. Tsujikawa T, Yoshida Y, Kiyono Y, et al. Functional oestrogen receptor a imaging in endometrial carcinoma using 16a-[18F]fluoro-17b-oestradiol PET. Eur J Nucl Med Mol Imaging 2011; 38:37-45.
30. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012; 30:587-592.
31. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586-592.
32. Fox JJ, Morris MJ, Larson SM, et al. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011; 50 (Suppl 1):39-48.
33. Ferrer Albiach C, Conde Moreno A, Rodríguez Cordón M, et al. Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment. Clin Transl Oncol 2010; 12:22-26.
34. Abolmaali N, Haase R, Koch A, et al. Two or four hour [18F] FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011; 50:22-27.
35. Yamane T, Kikuchi M, Shinohara S, et al. Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 2011; 13:227-231.
36. Chitneni SK, Palmer GM, Zalutsky MR, et al. Molecular imaging of hypoxia. J Nucl Med 2011; 52:165-168.
37. Höglund J, Shirvan A, Antoni G, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011; 52:720-725.